-
1
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008.
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
2
-
-
33750313208
-
Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on cancer stem cells
-
Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
-
(2006)
Cancer Res
, vol.66
, pp. 9339-9344
-
-
Clarke, M.F.1
Dick, J.E.2
Dirks, P.B.3
-
3
-
-
1542283717
-
Characterization of clonogenic multiple myeloma cells
-
Matsui W, Huff CA, Wang Q, et al: Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336, 2004.
-
(2004)
Blood
, vol.103
, pp. 2332-2336
-
-
Matsui, W.1
Huff, C.A.2
Wang, Q.3
-
4
-
-
0037085786
-
The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression
-
Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I and Brieva JA: The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99: 2154-2161, 2002.
-
(2002)
Blood
, vol.99
, pp. 2154-2161
-
-
Medina, F.1
Segundo, C.2
Campos-Caro, A.3
Gonzalez-Garcia, I.4
Brieva, J.A.5
-
5
-
-
8944235348
-
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
-
Wijdenes J, Vooijs WC, Clement C, et al: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94: 318-323, 1996.
-
(1996)
Br J Haematol
, vol.94
, pp. 318-323
-
-
Wijdenes, J.1
Vooijs, W.C.2
Clement, C.3
-
6
-
-
67449119398
-
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
-
Ikeda H, Hideshima T, Fulciniti M, et al: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15: 4028-4037, 2009.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4028-4037
-
-
Ikeda, H.1
Hideshima, T.2
Fulciniti, M.3
-
7
-
-
0031711326
-
Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
-
Witzig TE, Kimlinger T, Stenson M and Therneau T: Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31: 167-175, 1998.
-
(1998)
Leuk Lymphoma
, vol.31
, pp. 167-175
-
-
Witzig, T.E.1
Kimlinger, T.2
Stenson, M.3
Therneau, T.4
-
8
-
-
78349284733
-
Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma
-
Reid S, Yang S, Brown R, et al: Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 32: e190-e196, 2010.
-
(2010)
Int J Lab Hematol
, vol.32
-
-
Reid, S.1
Yang, S.2
Brown, R.3
-
9
-
-
84865011312
-
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
-
Kawano Y, Fujiwara S, Wada N, et al: Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol 41: 876-884, 2012.
-
(2012)
Int J Oncol
, vol.41
, pp. 876-884
-
-
Kawano, Y.1
Fujiwara, S.2
Wada, N.3
-
10
-
-
79955974540
-
Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications
-
Jakubikova J, Adamia S, Kost-Alimova M, et al: Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117: 4409-4419, 2011.
-
(2011)
Blood
, vol.117
, pp. 4409-4419
-
-
Jakubikova, J.1
Adamia, S.2
Kost-Alimova, M.3
-
11
-
-
84859905863
-
Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model
-
Van Valckenborgh E, Matsui W, Agarwal P, et al: Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 26: 1436-1439, 2012.
-
(2012)
Leukemia
, vol.26
, pp. 1436-1439
-
-
Van Valckenborgh, E.1
Matsui, W.2
Agarwal, P.3
-
12
-
-
84872345792
-
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
-
Chaidos A, Barnes CP, Cowan G, et al: Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 121: 318-328, 2013.
-
(2013)
Blood
, vol.121
, pp. 318-328
-
-
Chaidos, A.1
Barnes, C.P.2
Cowan, G.3
-
13
-
-
27744526844
-
The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
-
Yaccoby S: The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 11: 7599-7606, 2005.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7599-7606
-
-
Yaccoby, S.1
-
14
-
-
34548689859
-
Characterization of in vitro growth of multiple myeloma cells
-
Zlei M, Egert S, Wider D, Ihorst G, Wasch R and Engelhardt M: Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 35: 1550-1561, 2007.
-
(2007)
Exp Hematol
, vol.35
, pp. 1550-1561
-
-
Zlei, M.1
Egert, S.2
Wider, D.3
Ihorst, G.4
Wasch, R.5
Engelhardt, M.6
-
15
-
-
67349092202
-
Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6
-
Dezorella N, Pevsner-Fischer M, Deutsch V, et al: Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 315: 1904-1913, 2009.
-
(2009)
Exp Cell Res
, vol.315
, pp. 1904-1913
-
-
Dezorella, N.1
Pevsner-Fischer, M.2
Deutsch, V.3
-
16
-
-
77953229444
-
Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells
-
Fuhler GM, Baanstra M, Chesik D, et al: Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 316: 1816-1828, 2010.
-
(2010)
Exp Cell Res
, vol.316
, pp. 1816-1828
-
-
Fuhler, G.M.1
Baanstra, M.2
Chesik, D.3
-
17
-
-
24344440832
-
Hypoxia-induced dedifferentiation of tumor cells - A mechanism behind heterogeneity and aggressiveness of solid tumors
-
Axelson H, Fredlund E, Ovenberger M, Landberg G and Pahlman S: Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16: 554-563, 2005.
-
(2005)
Semin Cell Dev Biol
, vol.16
, pp. 554-563
-
-
Axelson, H.1
Fredlund, E.2
Ovenberger, M.3
Landberg, G.4
Pahlman, S.5
-
18
-
-
84862506605
-
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
-
Azab AK, Hu J, Quang P, et al: Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119: 5782-5794, 2012
-
(2012)
Blood
, vol.119
, pp. 5782-5794
-
-
Azab, A.K.1
Hu, J.2
Quang, P.3
-
19
-
-
0024359185
-
Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)
-
Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989.
-
(1989)
Br J Haematol
, vol.73
, pp. 199-204
-
-
Ohtsuki, T.1
Yawata, Y.2
Wada, H.3
Sugihara, T.4
Mori, M.5
Namba, M.6
-
20
-
-
0014115428
-
Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma
-
Matsuoka Y, Moore GE, Yagi Y and Pressman D: Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246-1250, 1967.
-
(1967)
Proc Soc Exp Biol Med
, vol.125
, pp. 1246-1250
-
-
Matsuoka, Y.1
Moore, G.E.2
Yagi, Y.3
Pressman, D.4
-
21
-
-
0035710746
-
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method
-
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
-
(2001)
Methods
, vol.25
, pp. 402-408
-
-
Livak, K.J.1
Schmittgen, T.D.2
-
22
-
-
84872548105
-
PDK1 inhibition is a novel therapeutic target in multiple myeloma
-
Fujiwara S, Kawano Y, Yuki H, et al: PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer 108: 170-178, 2013.
-
(2013)
Br J Cancer
, vol.108
, pp. 170-178
-
-
Fujiwara, S.1
Kawano, Y.2
Yuki, H.3
-
23
-
-
0031929051
-
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
-
Jourdan M, Ferlin M, Legouffe E, et al: The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100: 637-646, 1998.
-
(1998)
Br J Haematol
, vol.100
, pp. 637-646
-
-
Jourdan, M.1
Ferlin, M.2
Legouffe, E.3
-
24
-
-
0027500204
-
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
-
Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J and Sanderson RD: Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81: 767-774, 1993.
-
(1993)
Blood
, vol.81
, pp. 767-774
-
-
Ridley, R.C.1
Xiao, H.2
Hata, H.3
Woodliff, J.4
Epstein, J.5
Sanderson, R.D.6
-
25
-
-
47049120726
-
IRF4 addiction in multiple myeloma
-
Shaffer AL, Emre NC, Lamy L, et al: IRF4 addiction in multiple myeloma. Nature 454: 226-231, 2008.
-
(2008)
Nature
, vol.454
, pp. 226-231
-
-
Shaffer, A.L.1
Emre, N.C.2
Lamy, L.3
-
26
-
-
14944362858
-
Regulation of plasma-cell development
-
Shapiro-Shelef M and Calame K: Regulation of plasma-cell development. Nat Rev Immunol 5: 230-242, 2005.
-
(2005)
Nat Rev Immunol
, vol.5
, pp. 230-242
-
-
Shapiro-Shelef, M.1
Calame, K.2
-
27
-
-
34247527730
-
Hypoxia-inducible factors, stem cells, and cancer
-
Keith B and Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472, 2007.
-
(2007)
Cell
, vol.129
, pp. 465-472
-
-
Keith, B.1
Simon, M.C.2
-
28
-
-
79959908506
-
HIF induces human embryonic stem cell markers in cancer cells
-
Mathieu J, Zhang Z, Zhou W, et al: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652, 2011.
-
(2011)
Cancer Res
, vol.71
, pp. 4640-4652
-
-
Mathieu, J.1
Zhang, Z.2
Zhou, W.3
-
29
-
-
77958584577
-
Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms
-
Brennan SK, Wang Q, Tressler R, et al: Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 5: 2010.
-
(2010)
PLoS One
, vol.5
-
-
Brennan, S.K.1
Wang, Q.2
Tressler, R.3
-
30
-
-
0034795256
-
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
-
Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001.
-
(2001)
Nat Med
, vol.7
, pp. 1028-1034
-
-
Zhou, S.1
Schuetz, J.D.2
Bunting, K.D.3
-
31
-
-
78649646015
-
Retinoids regulate stem cell differentiation
-
Gudas LJ and Wagner JA: Retinoids regulate stem cell differentiation. J Cell Physiol 226: 322-330, 2011.
-
(2011)
J Cell Physiol
, vol.226
, pp. 322-330
-
-
Gudas, L.J.1
Wagner, J.A.2
-
32
-
-
68849097535
-
All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells
-
Huang H, Wu D, Fu J, et al: All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol 83: 191-202, 2009.
-
(2009)
Eur J Haematol
, vol.83
, pp. 191-202
-
-
Huang, H.1
Wu, D.2
Fu, J.3
-
33
-
-
84859625301
-
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma
-
Gu JL, Li J, Zhou ZH, et al: Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma. Biochem Biophys Res Commun 420: 644-650, 2012.
-
(2012)
Biochem Biophys Res Commun
, vol.420
, pp. 644-650
-
-
Gu, J.L.1
Li, J.2
Zhou, Z.H.3
-
34
-
-
60849117802
-
Suppression of Oct4 by germ cell nuclear factor restricts pluripotency and promotes neural stem cell development in the early neural lineage
-
Akamatsu W, DeVeale B, Okano H, Cooney AJ and van der Kooy D: Suppression of Oct4 by germ cell nuclear factor restricts pluripotency and promotes neural stem cell development in the early neural lineage. J Neurosci 29: 2113-2124, 2009.
-
(2009)
J Neurosci
, vol.29
, pp. 2113-2124
-
-
Akamatsu, W.1
DeVeale, B.2
Okano, H.3
Cooney, A.J.4
Van Der Kooy, D.5
-
35
-
-
25444473355
-
Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid-induced embryonic stem cell differentiation
-
Gu P, LeMenuet D, Chung AC, Mancini M, Wheeler DA and Cooney AJ: Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid-induced embryonic stem cell differentiation. Mol Cell Biol 25: 8507-8519, 2005.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 8507-8519
-
-
Gu, P.1
LeMenuet, D.2
Chung, A.C.3
Mancini, M.4
Wheeler, D.A.5
Cooney, A.J.6
-
36
-
-
84865862858
-
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
-
Hosen N, Matsuoka Y, Kishida S, et al: CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 26: 2135-2141, 2012.
-
(2012)
Leukemia
, vol.26
, pp. 2135-2141
-
-
Hosen, N.1
Matsuoka, Y.2
Kishida, S.3
-
37
-
-
0030720094
-
Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential
-
Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M and Kohgo Y: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482-491, 1997.
-
(1997)
Int J Cancer
, vol.74
, pp. 482-491
-
-
Matsumoto, A.1
Ono, M.2
Fujimoto, Y.3
Gallo, R.L.4
Bernfield, M.5
Kohgo, Y.6
-
38
-
-
77649187760
-
Sdc1 negatively modulates carcinoma cell motility and invasion
-
Ishikawa T and Kramer RH: Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 316: 951-965, 2010.
-
(2010)
Exp Cell Res
, vol.316
, pp. 951-965
-
-
Ishikawa, T.1
Kramer, R.H.2
-
39
-
-
77950559481
-
Heparanaseenhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis
-
Purushothaman A, Uyama T, Kobayashi F, et al: Heparanaseenhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115: 2449-2457, 2010.
-
(2010)
Blood
, vol.115
, pp. 2449-2457
-
-
Purushothaman, A.1
Uyama, T.2
Kobayashi, F.3
-
40
-
-
0027316197
-
Phenotypic difference of normal plasma cells from mature myeloma cells
-
Harada H, Kawano MM, Huang N, et al: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81: 2658-2663, 1993.
-
(1993)
Blood
, vol.81
, pp. 2658-2663
-
-
Harada, H.1
Kawano, M.M.2
Huang, N.3
-
41
-
-
77955795745
-
Hypoxia and activated VEGF/receptor pathway in multiple myeloma
-
Giatromanolaki A, Bai M, Margaritis D, et al: Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 30: 2831-2836, 2010.
-
(2010)
Anticancer Res
, vol.30
, pp. 2831-2836
-
-
Giatromanolaki, A.1
Bai, M.2
Margaritis, D.3
-
42
-
-
77952314832
-
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells
-
Martin SK, Diamond P, Williams SA, et al: Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95: 776-784, 2010.
-
(2010)
Haematologica
, vol.95
, pp. 776-784
-
-
Martin, S.K.1
Diamond, P.2
Williams, S.A.3
-
43
-
-
34247339604
-
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
-
Spisek R, Kukreja A, Chen LC, et al: Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204: 831-840, 2007.
-
(2007)
J Exp Med
, vol.204
, pp. 831-840
-
-
Spisek, R.1
Kukreja, A.2
Chen, L.C.3
-
44
-
-
84865860989
-
Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors
-
Ikegame A, Ozaki S, Tsuji D, et al: Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency- associated transcription factors. Leukemia 26: 2124-2134, 2012.
-
(2012)
Leukemia
, vol.26
, pp. 2124-2134
-
-
Ikegame, A.1
Ozaki, S.2
Tsuji, D.3
-
45
-
-
65049086409
-
Embryonic stem cell markers expression in cancers
-
Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J and Klein B: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383: 157-162, 2009.
-
(2009)
Biochem Biophys Res Commun
, vol.383
, pp. 157-162
-
-
Schoenhals, M.1
Kassambara, A.2
De Vos, J.3
Hose, D.4
Moreaux, J.5
Klein, B.6
|